Innovent Biologics Inc (HKEX: 01801), a China-based biopharmaceutical company, announced on Sunday that it has dosed its first patient with diabetic macular edema (DME) in the phase one study of IBI324, a potential first-in-class ophthalmic recombinant human anti-VEGF-A and anti-Ang-2 bispecific antibody.
This Phase 1 dose escalations study (CTR20221524) intends to assess the safety and tolerability of intravitreal injection of IBI324 in patients with DME.
IBI324 is a dual-target specific recombinant fully humanised anti-VEGF-A and anti-Ang-2 bispecific antibody developed by the company, which can achieve anti-angiogenesis, vascular stabilisation and inflammation inhibition by blocking both VEGF-A and Ang-2, aiming to provide more potential clinical benefits to DME patients, such as prolonging the dosing interval and improving treatment compliance.
vTv Therapeutics secures USD51m private placement for cadisegliatin Phase 3 study
AbbVie names new chief executive officer
SkinBioTherapeutics expands foot care products in AMEA with Dermatonics partnership
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Insulet's Omnipod 5 integration with Abbott FreeStyle Libre 2 Plus Sensor secures CE Mark approval
Kyowa Kirin enrols first subject in phase two tivozanib eye drops (KHK4951) clinical trial
China accepts GSK's Shingrix application for at-risk adults
Novo Nordisk to boost manufacturing capacity with acquisition of three fill-finish sites
Breye Therapeutics commences phase 1b/2a danegaptide clinical trial
DexCom Inc breaks ground on new manufacturing facility in Ireland
VibroSense Dynamics AB secures provisional patent for chemotherapy-induced nerve damage prediction
Innovent Biologics signs collaboration agreement with Sanegene Bio USA
Japan approves GSK's filing for Arexvy vaccination for at-risk adults